Abstract
This is the protocol for a review and there is no abstract. The objectives are as follows: In order to evaluate the therapeutical benefit of idiotype vaccination in the treatment of NHL we will particularly analyse overall survival (OS) as the primary endpoint; as well as progression-free survival (PFS), response rate, treatment-related mortality, adverse events and quality of life as secondary endpoints. We will analyse these outcome parameters critically and systematically with respect to different vaccine formulations, dosages or time schedules in the experimental arm and placebo or no other treatment in the control arm.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
